Ayala Pharmaceuticals Revenue

In the year 2023, Ayala Pharmaceuticals had annual revenue of $13.00K, down -98.12%.

Revenue

13.00K

Revenue Growth

-98.12%

P/S Ratio

456.22

Revenue / Employee

619.05

Employees

Market Cap

5.93M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	13.00K	-679.00K	-98.12%
Dec 31, 2022	692.00K	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Ayala Pharmaceuticals News

4 months ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire
4 months ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline - Business Wire
1 year ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
1 year ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
1 year ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
1 year ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
1 year ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
1 year ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire

More News